Premium
Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program
Author(s) -
Carol Hernan,
Lock Richard,
Houghton Peter J.,
Morton Christopher L.,
Kolb E. Anders,
Gorlick Richard,
Reynolds C. Patrick,
Maris John M.,
Keir Stephen T.,
Billups Catherine A.,
Smith Malcolm A.
Publication year - 2009
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.22056
Subject(s) - in vivo , osteosarcoma , medicine , sarcoma , wilms' tumor , vincristine , in vitro , toxicity , preclinical testing , pathology , pharmacology , cancer research , chemotherapy , cyclophosphamide , biology , biochemistry , microbiology and biotechnology , medical physics
Background Ispinesib is a highly specific inhibitor of kinesin spindle protein (KSP, HsEg5), a mitotic kinesin required for separation of the spindle poles. Here we report the activity of ispinesib against the in vitro and in vivo panels of the Pediatric Preclinical Testing Program (PPTP). Procedures Ispinesib was tested against the PPTP in vitro panel cell lines at concentrations from 0.1 nM to 1 µM and against the in vivo tumor panel xenografts by intraperitoneal administration (5 or 10 mg/kg) every 4 days for 3 doses repeated at day 21. Results Ispinesib was highly potent against the PPTP's in vitro cell lines with a median IC 50 of 4.1 nM. Ispinesib (10 mg/kg) induced unexplained toxicity in mice bearing osteosarcoma xenografts and exceeded the MTD in 12 of 40 non‐osteosarcoma xenografts. Ispinesib induced significant tumor growth delay in 88% (23/26) of evaluable xenografts. Using a time to event measure of efficacy, ispinesib had intermediate and high levels of activity against 4 (21%) and 5 (26%) of the 19 evaluable solid tumor xenografts, respectively. Ispinesib induced maintained complete responses (CR) in a rhabdoid tumor, a Wilms tumor and a Ewing sarcoma xenograft. Ispinesib (5 mg/kg) produced 2 complete and 2 partial responses among 6 evaluable xenografts in the ALL panel. The in vivo pattern of activity was distinctive from that previously reported for vincristine. Conclusions Ispinesib demonstrated broad in vivo antitumor activity, including maintained complete responses for several xenografts, although with high toxicity rates at the doses studied. Pediatr Blood Cancer 2009; 53:1255–1263. © 2009 Wiley‐Liss, Inc.